← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Retinoids for cancer treatment
tretinoin
L01XF01
Forms & Strengths
- Capsules: 10mg
- Injection: 10mg/mL, for IV use
Adult Dosing
- 45mg/m^2/day, in 2-3 divided doses, for induction in APL
- Dosage may be adjusted based on response and tolerance
Pediatric Dosing
- Dosing for pediatric patients with APL has not been established
- Clinical experience with pediatric use is limited
Indications
- Treatment of acute promyelocytic leukemia (APL)
- Induction of remission in APL
Mechanism of Action
- Differentiation of immature granulocytes to mature cells
- Induces apoptosis in APL cells
- Regulates gene expression through retinoic acid receptors
Contraindications
- Hypersensitivity to tretinoin or other retinoids
- Severe liver or kidney impairment
Adverse Reactions
- Headache, dizziness, fatigue, and weakness
- Nausea, vomiting, and diarrhea
- Pseudotumor cerebri, and retinoic acid syndrome
Drug Interactions
- Concomitant use with vitamin A may increase toxicity risk
- CYP3A4 inhibitors may increase tretinoin levels
- Co-administration with other hepatotoxic agents may increase liver damage
Curated Content: Needs Vetting Before Put to Clinical Use